Skip to main content
NCBI home page
Archives of Disease in Childhood. Fetal and Neonatal Edition logoLink to Archives of Disease in Childhood. Fetal and Neonatal Edition
. 1998 Jan;78(1):F10–F14. doi: 10.1136/fn.78.1.f10

Randomised trial of erythromycin on the development of chronic lung disease in preterm infants

A Lyon, J McColm, L Middlemist, S Fergusson, N McIntosh, P Ross
PMCID: PMC1720741  PMID: 9536833

Abstract

AIMS—To determine if erythromycin given from birth reduces the inflammatory response and the incidence and severity of chronic lung disease.
METHODS—Seventy five infants less than 30 weeks of gestation and ventilated from birth for lung disease were randomly assigned to receive erythromycin intravenously for 7 days or to no treatment. Ureaplasma urealyticum was detected in tracheal secretions by culture and polymerase chain reaction. Differential cell counts were obtained from bronchoalveolar lavage fluid collected daily for 5 days and concentrations of the cytokines interluekins IL-1β and IL-8, and tumour necrosis factor α (TNF-α) were measured. Chronic lung disease (CLD) was defined as oxygen dependency at 36 weeks of gestation.
RESULTS—Nine infants (13%) were positive for U urealyticum. The inflammatory cytokines in the lungs increased over the first 5 days of life in all babies, but no association was found between their concentrations and the development of CLD. Those treated with erythromycin showed no significant differences from the non- treated group in the differential cell counts or concentrations of the cytokines. The two groups had a similar incidence of CLD. Babies infected with U urealyticum did not have a more pronounced cytokine response than those without infection. Chorioamnionitis was associated with significantly higher concentrations of IL-1β and IL-8 on admission: these babies had less severe acute lung disease and developed significantly less CLD.
CONCLUSIONS—U urealyticum in the trachea was not associated with an increased inflammatory response in preterm infants. Erythromycin did not reduce the incidence or severity of CLD.



Full Text

The Full Text of this article is available as a PDF (132.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bagchi A., Viscardi R. M., Taciak V., Ensor J. E., McCrea K. A., Hasday J. D. Increased activity of interleukin-6 but not tumor necrosis factor-alpha in lung lavage of premature infants is associated with the development of bronchopulmonary dysplasia. Pediatr Res. 1994 Aug;36(2):244–252. doi: 10.1203/00006450-199408000-00017. [DOI] [PubMed] [Google Scholar]
  2. Carr R., Huizinga T. W., Kleijer M., Davies J. M. Changes in plasma FcRIII demonstrate increasing receptor production during late pregnancy and after preterm birth. Pediatr Res. 1992 Nov;32(5):505–508. doi: 10.1203/00006450-199211000-00001. [DOI] [PubMed] [Google Scholar]
  3. Cassell G. H., Waites K. B., Crouse D. T., Rudd P. T., Canupp K. C., Stagno S., Cutter G. R. Association of Ureaplasma urealyticum infection of the lower respiratory tract with chronic lung disease and death in very-low-birth-weight infants. Lancet. 1988 Jul 30;2(8605):240–245. doi: 10.1016/s0140-6736(88)92536-6. [DOI] [PubMed] [Google Scholar]
  4. Cassell G. H., Waites K. B., Watson H. L., Crouse D. T., Harasawa R. Ureaplasma urealyticum intrauterine infection: role in prematurity and disease in newborns. Clin Microbiol Rev. 1993 Jan;6(1):69–87. doi: 10.1128/cmr.6.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cunliffe N. A., Fergusson S., Davidson F., Lyon A., Ross P. W. Comparison of culture with the polymerase chain reaction for detection of Ureaplasma urealyticum in endotracheal aspirates of preterm infants. J Med Microbiol. 1996 Jul;45(1):27–30. doi: 10.1099/00222615-45-1-27. [DOI] [PubMed] [Google Scholar]
  6. Farrell P. M., Avery M. E. Hyaline membrane disease. Am Rev Respir Dis. 1975 May;111(5):657–688. doi: 10.1164/arrd.1975.111.5.657. [DOI] [PubMed] [Google Scholar]
  7. Groneck P., Goetze-Speer B., Speer C. P. Inflammatory bronchopulmonary response of preterm infants with microbial colonisation of the airways at birth. Arch Dis Child Fetal Neonatal Ed. 1996 Jan;74(1):F51–F55. doi: 10.1136/fn.74.1.f51. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Hillier S. L., Martius J., Krohn M., Kiviat N., Holmes K. K., Eschenbach D. A. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med. 1988 Oct 13;319(15):972–978. doi: 10.1056/NEJM198810133191503. [DOI] [PubMed] [Google Scholar]
  9. Ichikawa Y., Ninomiya H., Koga H., Tanaka M., Kinoshita M., Tokunaga N., Yano T., Oizumi K. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. Am Rev Respir Dis. 1992 Jul;146(1):196–203. doi: 10.1164/ajrccm/146.1.196. [DOI] [PubMed] [Google Scholar]
  10. Iles R., Edmunds A. T. Assessment of pulmonary function in resolving chronic lung disease of prematurity. Arch Dis Child Fetal Neonatal Ed. 1997 Mar;76(2):F113–F117. doi: 10.1136/fn.76.2.f113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Iles R., Lyon A., Ross P., McIntosh N. Infection with Ureaplasma urealyticum and Mycoplasma hominis and the development of chronic lung disease in preterm infants. Acta Paediatr. 1996 Apr;85(4):482–484. doi: 10.1111/j.1651-2227.1996.tb14067.x. [DOI] [PubMed] [Google Scholar]
  12. Jones C. A., Cayabyab R. G., Kwong K. Y., Stotts C., Wong B., Hamdan H., Minoo P., deLemos R. A. Undetectable interleukin (IL)-10 and persistent IL-8 expression early in hyaline membrane disease: a possible developmental basis for the predisposition to chronic lung inflammation in preterm newborns. Pediatr Res. 1996 Jun;39(6):966–975. doi: 10.1203/00006450-199606000-00007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. McColm J. R., McIntosh N. Interleukin-8 in bronchoalveolar lavage samples as predictor of chronic lung disease in premature infants. Lancet. 1994 Mar 19;343(8899):729–729. doi: 10.1016/s0140-6736(94)91606-3. [DOI] [PubMed] [Google Scholar]
  14. Nelson S., Summer W. R., Terry P. B., Warr G. A., Jakab G. J. Erythromycin-induced suppression of pulmonary antibacterial defenses. A potential mechanism of superinfection in the lung. Am Rev Respir Dis. 1987 Nov;136(5):1207–1212. doi: 10.1164/ajrccm/136.5.1207. [DOI] [PubMed] [Google Scholar]
  15. Northway W. H., Jr Bronchopulmonary dysplasia: then and now. Arch Dis Child. 1990 Oct;65(10 Spec No):1076–1081. doi: 10.1136/adc.65.10_spec_no.1076. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Oishi K., Sonoda F., Kobayashi S., Iwagaki A., Nagatake T., Matsushima K., Matsumoto K. Role of interleukin-8 (IL-8) and an inhibitory effect of erythromycin on IL-8 release in the airways of patients with chronic airway diseases. Infect Immun. 1994 Oct;62(10):4145–4152. doi: 10.1128/iai.62.10.4145-4152.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Shennan A. T., Dunn M. S., Ohlsson A., Lennox K., Hoskins E. M. Abnormal pulmonary outcomes in premature infants: prediction from oxygen requirement in the neonatal period. Pediatrics. 1988 Oct;82(4):527–532. [PubMed] [Google Scholar]
  18. Watterberg K. L., Demers L. M., Scott S. M., Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996 Feb;97(2):210–215. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood. Fetal and Neonatal Edition are provided here courtesy of BMJ Publishing Group

RESOURCES